Autologous bone marrow transplantation for pediatric Wilms' tumor: The experience of the European bone marrow transplantation solid tumor registry

Publisher Website
Google Scholar
Abstract
This survey includes 25 children with Wilms' tumor undergoing high‐dose chemotherapy associated with autologous bone marrow transplantation (ABMT) in the period June 1984‐December 1991 and enrolled in the European Bone Marrow Transplantation Registry for Solid Tumors. At diagnosis, 12 children presented stage IV disease, 5 stage III, 3 stage II, and 5 stage I. Before ABMT, 21 children had 1 to 4 relapses (median 1); 13 achieved a second or subsequent complete remission (CR), four stage IV children failed to respond to first line treatment and achieved either CR (3 patients), or partial remission (PR) after second line therapy. At high‐dose chemotherapy, 17 children were in CR and 8 had measurable disease. Seven different high‐dose regimens were administered, even if 20 children received melphalan mostly associated with vincristine and 8 involved field radiotherapy. Three children died early of pneumonitis; 2 developed an acute transient renal failure, 1 a chronic renal failure. Out of the 8 children with target disease at graft, 2 died of toxicity, 5 achieved CR, 1 obtained PR, and only 1 is presently alive in CCR at 39 months after ABMT. Of the 17 children grafted in CR, 8 are alive event‐free at 14‐90 months (median 34) from ABMT; 7 relapsed at 3‐23 months (median 7 months); 1 died of toxicity and 1 was lost to follow‐up in CR at 12 months. A salvage attempt with high‐dose chemotherapy in children with resistant or poor prognosis recurrent Wilms' tumor seems to be justified. An international cooperative protocol taking into account the increased risk of lung and renal toxicity is necessary.